The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Coronary microvascular dysfunction in hypertrophy and heart failure
Abstract
Left ventricular (LV) hypertrophy (LVH) is a growth in left myocardial mass mainly caused by increased cardiomyocyte size. LVH can be a physiological adaptation to physical exercise or a pathological condition either primary, i.e. genetic, or secondary to LV overload. Patients with both primary and secondary LVH have evidence of coronary microvascular dysfunction (CMD). The latter is mainly due to capillary rarefaction and adverse remodelling of intramural coronary arterioles due to medial wall thickening with an increased wall/lumen ratio. An important feature of this phenomenon is the diffuse nature of this remodelling, which generally affects the coronary microvessels in the whole of the left ventricle. Patients with LVH secondary to arterial hypertension can develop both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). These patients can develop HFrEF via a ‘direct pathway’ with an interval myocardial infarction and also in its absence. On the other hand, patients can develop HFpEF that can then progress to HFrEF with or without interval myocardial infarction. A similar evolution towards LV dysfunction and both HFpEF and HFrEF can occur in patients with hypertrophic cardiomyopathy, the most common genetic cardiomyopathy with a phenotype characterized by massive LVH. In this review article, we will discuss both the experimental and clinical studies explaining the mechanisms responsible for CMD in LVH as well as the evidence linking CMD with HFpEF and HFrEF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Self-citationNahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.-L., Libby, P., Weissleder, R., & Pittet, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070885 · Cited by 2,300
Hypertrophic Cardiomyopathy: A Systematic Review
Maron, B. J. (2002) · JAMA · doi:10.1001/jama.287.10.1308 · Cited by 2,224
Revisiting Cardiac Cellular Composition
Pinto, A. R., Ilinykh, A., Ivey, M. J., Kuwabara, J. T., D’Antoni, M. L., Debuque, R., Chandran, A., Wang, L., Arora, K., Rosenthal, N. A., et al. (2016) · Circulation Research · doi:10.1161/circresaha.115.307778 · Cited by 1,400 · cited 1×
“cardiomyocytes Endothelial cells are the main non-cardiomyocyte cell type present in the heart.(99)”
BackgroundMohammed, S. F., Hussain, S., Mirzoyev, S. A., Edwards, W. D., Maleszewski, J. J., & Redfield, M. M. (2015) · Circulation · doi:10.1161/circulationaha.114.009625 · Cited by 874 · cited 16×
“Impact of coronary microvascular/endothelial dysfunction on cardiac fibrosis Impaired coronary microvascular density correlates with cardiac fibrosis in HFpEF.72 Endothelial dysfunction can trigger cardiac fibrosis by different means.”
BackgroundInfluentialBrutsaert, D. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00017.2002 · Cited by 697 · cited 1×
“role in cardiovascular homeostasis by regulating vascular wall permeability, vasomotor tone, and cardiac function.(77) It protects against mechanical stimuli such as pressure and”
BackgroundShah, S. J., Lam, C. S. P., Svedlund, S., Saraste, A., Hage, C., Tan, R.-S., Beussink-Nelson, L., Ljung Faxén, U., Fermer, M. L., Broberg, M. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy531 · Cited by 656
Westermann, D., Lindner, D., Kasner, M., Zietsch, C., Savvatis, K., Escher, F., von Schlippenbach, J., Skurk, C., Steendijk, P., Riad, A., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.931451 · Cited by 644
Self-citationRajappan, K., Rimoldi, O. E., Dutka, D. P., Ariff, B., Pennell, D. J., Sheridan, D. J., & Camici, P. G. (2002) · Circulation · doi:10.1161/hc0402.102931 · Cited by 358
Self-citationRakusan, K., Flanagan, M. F., Geva, T., Southern, J., & Van Praagh, R. (1992) · Circulation · doi:10.1161/01.cir.86.1.38 · Cited by 327
Cited by
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases
Del Buono, M. G., Montone, R. A., Camilli, M., Carbone, S., Narula, J., Lavie, C. J., Niccoli, G., & Crea, F. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.042 · Cited by 635
Pop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 399
Coronary Microvascular Dysfunction
Vancheri, F., Longo, G., Vancheri, S., & Henein, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092880 · Cited by 321
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Roadmap for alleviating the manifestations of ageing in the cardiovascular system
Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59
“Age-dependent EC dysfunction and large-artery stiffening increase LV afterload and lead to compensatory LV hypertrophy and subsequently increased LV oxygen demand 71,184 .”
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Metadata
- Authors
- Camici, P. G., Tschöpe, C., Di Carli, M. F., Rimoldi, O., & Van Linthout, S.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-30
- Volume
- 116
- Issue
- 4
- Pages
- 806-816
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W3004147923
- Cited by
- 203
- References
- 11
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.